- Author:
Lian-shu HAN
1
;
Sheng-nan WU
;
Jun YE
;
Wen-juan QIU
;
Hui-wen ZHANG
;
Xiao-lan GAO
;
Yu WANG
;
Xiao-yan LI
;
Hao XU
;
Xue-fan GU
Author Information
- Publication Type:Journal Article
- MeSH: Amino Acid Metabolism, Inborn Errors; diagnosis; diet therapy; enzymology; metabolism; Carnitine; metabolism; Child; Child, Preschool; Diet, Protein-Restricted; utilization; Female; Follow-Up Studies; Humans; Infant; Infant, Newborn; Male; Methylmalonyl-CoA Mutase; genetics; Retrospective Studies
- From: Chinese Journal of Medical Genetics 2013;30(5):589-593
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo explore the clinical feature, therapeutic effect and prognosis of isolated methylmalonic acidemia.
METHODSThe clinical characteristics, laboratory findings, treatment and outcome of 40 patients were retrospectively analyzed. The main treatment was a low-protein diet supplemented with L-carnitine and special milk free of leucine, valine, threonine and methionine. Vitamin B12 was also given to cobalamin responders. The patients were followed up every 1-3 months.
RESULTSMutations in the MUT gene were identified in 30 of 33 patients who had accepted DNA testing. Thirty cases were treated and followed up regularly for from 1 month to 8 years. Eight cases had died, 8 had developed normal intelligence, among whom 4 from newborn screening were asymptomatic. Psychomotor developmental delay and mental retardation were present in 14 cases. The propionylcarnitine level, ratio of propionylcarnitine/acetylcarnitine in blood, methylmalonic acid and methylcitric acid levels in urine have decreased significantly, with the median values reduced respectively from 24.15 (7.92-81.02) μmol/L, 1.08 (0.38-6.01), 705.34 (113.79-3078.60) and 7.71 (0.52-128.21) to 10.50 (3.00-30.92) μmol/L, 0.63 (0.25-2.89), 166.23 (22.40-3322.21) and 3.96 (0.94-119.13) (P < 0.05).
CONCLUSIONThe prognosis of isolated methylmalonic acidemia may be predicted with the enzymatic subgroup, age at onset and cobalamin responsiveness. Outcome is unfavorable in neonatal patients and those who were non-responsive to cobalamin.